DrugsControl Media Services

News Detail

Sun Pharma inks Non-exclusive License Agreement with Takeda to introduce Vonoprazan tablets in India (22-06-2024)

New Delhi, 22 June 2024: Sun Pharmaceutical Industries on Friday said it has inked a licensing pact with Takeda Pharmaceutical Company to commercialise a novel gastrointestinal drug in India.

The company has entered into a non-exclusive patent licensing agreement with ......
View Details

Source : Business Standard
Takeda Pharmaceutical Company Sun Pharma Pharmaceutical industry Healthcare in India Generic Pharmaceuticals Pharmaceuticals (NEC) acid peptic disorders FDA Major GERD Sun Pharmaceutical Industries Erosive esophagitis CEO Vonoprazan leader healthcare practitioners Mumbai infection Gastroesophageal Reflux Disease India clarithromycin Kirti Ganorkar amoxicillin reflux esophagitis

Related News